8-K: Veracyte Reports Strong Q4 and Full Year 2024 Financial Results, Driven by Testing Revenue Growth

Veracyte announces a 21% increase in fourth-quarter total revenue to $118.6 million and a 23% increase in full-year total revenue to $445.8 million, driven by strong growth in testing revenue.

Summary

• Veracyte reported its fourth quarter and full year 2024 financial results on February 24, 2025.
• The company's fourth-quarter total revenue increased by 21% to $118.6 million, while testing revenue grew by 24% to $112.2 million.
• Total testing volume increased by 22% to 41,271 tests, with Decipher volume growing by 45% and Afirma volume by 8%.
• Net income for the fourth quarter was $5.1 million, representing 4.3% of revenue, and adjusted EBITDA was $26.1 million, or 22.0% of revenue.
• For the full year 2024, total revenue increased by 23% to $445.8 million, and testing revenue increased by 28% to $419.0 million.
• Full-year net income was $24.1 million, or 5.4% of revenue, and adjusted EBITDA was $91.9 million, or 20.6% of revenue.
• The company generated $75.1 million in cash from operations and ended the year with $289.4 million in cash, cash equivalents, and short-term investments.
• Veracyte expects 2025 testing revenue to be in the range of $470 million to $480 million, representing 12% to 15% year-over-year growth.
• Adjusted EBITDA as a percentage of revenue in 2025 is expected to be approximately 21.6%.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, revenue growth, and strategic advancements. However, the potential restructuring of the French subsidiary introduces some uncertainty.

Positives

• Veracyte achieved record revenue in Q4 2024.
• The company delivered its 10th consecutive quarter of 20% or greater testing revenue growth.
• Net income and adjusted EBITDA significantly improved in both Q4 and full-year 2024.
• The company generated substantial cash from operations.
• Veracyte has a strong cash position with $289.4 million in cash, cash equivalents, and short-term investments.
• Decipher is the only gene expression test included in V1.2025 of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer published in December 2024.
• Veracyte received approval from Molecular Diagnostic Services Program (MolDx) for the technical assessment submission for Decipher for use in the metastatic population.

Negatives

• Product revenue decreased by 18% in Q4 2024 compared to Q4 2023, from $3.7 million to $3.0 million.
• Biopharmaceutical and other revenue decreased by 17% in Q4 2024 compared to Q4 2023, from $4.1 million to $3.5 million.
• Product revenue decreased by 12% for the full year 2024 compared to 2023, from $15.6 million to $13.7 million.
• Biopharmaceutical and other revenue decreased by 30% for the full year 2024 compared to 2023, from $18.9 million to $13.2 million.
• Veracyte is evaluating its ownership and operations of the company's French subsidiary, Veracyte SAS, and may be required to begin bankruptcy proceedings following its works council consultation period.

Risks

• The company's ability to launch, commercialize, and receive reimbursement for its products is subject to risks and uncertainties.
• Executing business strategies related to the C2i Genomics acquisition, including integration and realization of expected benefits, involves risks.
• Demonstrating the validity and utility of genomic tests and biopharma offerings is crucial for success.
• Scaling global operations and enhancing the internal control environment pose challenges.
• The war in Ukraine and other regional conflicts could impact European economies and Veracyte's facilities in France.
• Foreign currency fluctuations, volatile interest rates, inflation, and turmoil in the global banking and finance system could affect financial results.
• The ongoing conflicts in Russia and Ukraine and in the Middle East and the performance and utility of our tests in the clinical environment could affect financial results.
• Veracyte SAS may be required to begin bankruptcy proceedings following its works council consultation period.

Future Outlook

Veracyte expects 2025 testing revenue to be in the range of $470 million to $480 million, representing 12% to 15% year-over-year growth, and adjusted EBITDA as a percentage of revenue to be approximately 21.6%.

Management Comments

• Marc Stapley, Veracyte's chief executive officer, stated that he is incredibly proud of what the team accomplished in 2024.
• He noted the exceptional performance in Q4, delivering record revenue and achieving the 10th consecutive quarter of 20% or greater testing revenue growth.
• He sees significant opportunities for Decipher and Afirma to impact more patients and drive growth for Veracyte in 2025.
• He stated that the company is focused on moving forward with its exciting portfolio of strategic growth drivers while maintaining financial discipline.

Industry Context

Veracyte's focus on genomic testing and strategic acquisitions like C2i Genomics positions it well in the growing market for precision medicine and cancer diagnostics. The inclusion of Decipher in the NCCN guidelines further validates its clinical utility and supports adoption by healthcare providers.

Comparison to Industry Standards

• Veracyte's revenue growth of 23% for the full year 2024 is strong compared to other diagnostic companies.
• Companies like Exact Sciences and Guardant Health, which also focus on cancer diagnostics, have seen similar growth rates in recent years.
• Veracyte's adjusted EBITDA margin of 20.6% is also competitive within the industry.
• The company's cash position of $289.4 million provides a solid foundation for future growth and strategic investments.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and improved profitability.
• Employees may be affected by the potential restructuring of the French subsidiary.
• Customers will benefit from the continued development and commercialization of Veracyte's diagnostic tests.
• Suppliers and creditors may be impacted by the potential restructuring of the French subsidiary.

Next Steps

• Veracyte will continue to focus on its strategic growth drivers, including Decipher and Afirma.
• The company will provide further details on the process and potential impact of its Marseille, France operations during the conference call.
• Veracyte will provide its total revenue outlook for 2025 once there is more clarity on the timing and impact of the process underway with Veracyte SAS.

Key Dates

Keywords

Veracyte, financial results, testing revenue, Decipher, Afirma, genomic tests, cancer diagnostics, EBITDA, revenue growth